SSGJ-707

• Target:

  PD-1/PD-L1|||VEGFR

• Related Pathways:

  Apoptosis|||Tyrosine Kinase/Adaptors|||Angiogenesis|||Immunology/Inflammation|||Cell Cycle/Checkpoint

• Bioactivity:

  SSGJ-707 is a bispecific recombinant humanized IgG4 monoclonal antibody inhibitor that targets PD-1 and VEGF. It is applicable in cancer research, particularly for advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer.

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C